T-cell Non-Hodgkin Lymphoma Clinical Trials

12 recruitingLast updated: June 17, 2026

There are 12 actively recruiting t-cell non-hodgkin lymphoma clinical trials across 3 countries. Studies span Phase 1, Phase 2. Top locations include Philadelphia, Pennsylvania, United States, Scottsdale, Arizona, United States, Rochester, Minnesota, United States. Updated daily from ClinicalTrials.gov.


T-cell Non-Hodgkin Lymphoma Trials at a Glance

12 actively recruiting trials for t-cell non-hodgkin lymphoma are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 1 with 9 trials, with the heaviest enrollment activity in Philadelphia, Scottsdale, and Rochester. Lead sponsors running t-cell non-hodgkin lymphoma studies include City of Hope Medical Center, Beijing GoBroad Hospital, and Mayo Clinic.

Browse t-cell non-hodgkin lymphoma trials by phase

Treatments under study

About T-cell Non-Hodgkin Lymphoma Clinical Trials

Looking for clinical trials for T-cell Non-Hodgkin Lymphoma? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new T-cell Non-Hodgkin Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about T-cell Non-Hodgkin Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 1Phase 2

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Recurrent Mycosis FungoidesRefractory Mycosis FungoidesSezary Syndrome+5 more
City of Hope Medical Center78 enrolled4 locationsNCT03011814
Recruiting
Phase 1

CD45BE-HSPC + CART-45 Cells

Hodgkin LymphomaRichter's TransformationT-cell Non-Hodgkin Lymphoma+1 more
University of Pennsylvania42 enrolled1 locationNCT07451054
Recruiting
Phase 1

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Myelodysplastic SyndromeB-cell Non Hodgkin LymphomaRefractory Acute Myeloid Leukemia+16 more
Mayo Clinic99 enrolled2 locationsNCT03017820
Recruiting
Phase 1Phase 2

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

Recurrent T-Cell Non-Hodgkin LymphomaRefractory T-Cell Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center50 enrolled1 locationNCT07225985
Recruiting
Phase 2

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

T-cell LymphomaT-cell Prolymphocytic LeukemiaLymphoma, T-Cell+5 more
Jonathan Brammer44 enrolled1 locationNCT07356245
Recruiting
Phase 1

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

Recurrent Adult T-Cell Leukemia/LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Adult T-Cell Leukemia/Lymphoma+1 more
John Reneau12 enrolled1 locationNCT04848064
Recruiting
Phase 1

CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)

T-cell Non-Hodgkin Lymphoma
Vittoria Biotherapeutics30 enrolled2 locationsNCT06420089
Recruiting
Phase 2

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

Primary Cutaneous T-Cell Non-Hodgkin LymphomaStage IB Mycosis Fungoides and Sezary Syndrome AJCC v8Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8+5 more
City of Hope Medical Center34 enrolled3 locationsNCT04930653
Recruiting
Phase 1

Q702 for the Treatment of Patients With Hematologic Malignancies

Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant Histiocytosis+34 more
Mayo Clinic46 enrolled2 locationsNCT06712810
Recruiting
Phase 1Phase 2

CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas

T-cell Non-Hodgkin LymphomaT-cell Lymphoma (PTCL and CTCL)
Beijing GoBroad Hospital36 enrolled3 locationsNCT07022964
Recruiting
Phase 1Phase 2

CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas

T-cell Non-Hodgkin LymphomaT-cell Lymphoma (PTCL and CTCL)
Beijing GoBroad Hospital36 enrolled4 locationsNCT06925464
Recruiting
Phase 2

Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas

Lymphoma, Extranodal NK-T-CellT-cell Non-Hodgkin Lymphoma
Keimyung University Dongsan Medical Center34 enrolled2 locationsNCT02859402